News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
44,292 Results
Type
Article (4084)
Company Profile (5)
Press Release (40203)
Section
Business (12964)
Career Advice (89)
Deals (2368)
Drug Delivery (9)
Drug Development (6399)
Employer Resources (6)
FDA (1289)
Job Trends (1052)
News (23091)
Policy (2295)
Tag
2024 Biotech Bay Standard (1)
2024 Genetown Standard (1)
Academia (126)
Allergies (19)
Alliances (3795)
ALS (10)
Alzheimer's disease (44)
Antibody-drug conjugate (ADC) (7)
Approvals (1301)
Artificial intelligence (17)
Autoimmune disease (6)
Bankruptcy (10)
Best Places to Work (749)
Biosimilars (8)
Biotechnology (2)
Bladder cancer (2)
Brain cancer (4)
Breast cancer (20)
Cancer (161)
Cardiovascular disease (12)
Career advice (70)
CAR-T (5)
Cell therapy (21)
Cervical cancer (1)
Clinical research (5254)
Collaboration (50)
Compensation (4)
Complete response letters (4)
COVID-19 (337)
CRISPR (2)
C-suite (24)
Cystic fibrosis (7)
Data (186)
Diabetes (31)
Diagnostics (319)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (10)
Duchenne muscular dystrophy (7)
Earnings (4271)
Editorial (4)
Employer branding (2)
Employer resources (5)
Events (4688)
Executive appointments (57)
FDA (1360)
Featured Employer (1)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (52)
Gene editing (6)
Generative AI (2)
Gene therapy (32)
GLP-1 (136)
Government (319)
Grass and pollen (2)
Guidances (6)
Healthcare (903)
Huntington's disease (3)
Immunology and inflammation (17)
Indications (6)
Infectious disease (353)
Inflammatory bowel disease (12)
Inflation Reduction Act (1)
Influenza (5)
Intellectual property (5)
Interviews (12)
IPO (704)
IRA (3)
Job creations (350)
Job search strategy (70)
Labor market (1)
Layoffs (59)
Legal (436)
Liver cancer (4)
Lung cancer (22)
Lymphoma (10)
Machine learning (1)
Management (2)
Manufacturing (18)
MASH (13)
Medical device (733)
Medtech (733)
Mergers & acquisitions (1688)
Metabolic disorders (70)
Multiple sclerosis (15)
NASH (4)
Neurodegenerative disease (8)
Neuropsychiatric disorders (1)
Neuroscience (90)
NextGen: Class of 2025 (260)
Non-profit (182)
Northern California (167)
Obesity (21)
Opinion (29)
Ovarian cancer (2)
Pain (6)
Pancreatic cancer (9)
Parkinson's disease (6)
Patents (10)
Patient recruitment (10)
Peanut (14)
People (4243)
Pharmaceutical (1)
Pharmacy benefit managers (2)
Phase I (1400)
Phase II (2178)
Phase III (2266)
Pipeline (101)
Podcasts (9)
Policy (5)
Postmarket research (258)
Preclinical (539)
Press Release (2)
Prostate cancer (9)
Psychedelics (1)
Radiopharmaceuticals (20)
Rare diseases (32)
Real estate (415)
Recruiting (3)
Regulatory (1727)
Reports (10)
Research institute (137)
Resumes & cover letters (12)
RNA editing (1)
RSV (5)
Schizophrenia (2)
Series A (9)
Series B (11)
Sickle cell disease (1)
Southern California (57)
Special edition (3)
Spinal muscular atrophy (11)
Startups (286)
Stomach cancer (1)
Supply chain (4)
The Weekly (9)
United States (822)
Vaccines (101)
Venture capitalists (3)
Webinars (1)
Weight loss (19)
Date
Today (12)
Last 7 days (50)
Last 30 days (190)
Last 365 days (2546)
2025 (676)
2024 (2365)
2023 (2620)
2022 (5696)
2021 (3863)
2020 (3012)
2019 (2456)
2018 (1940)
2017 (2681)
2016 (2419)
2015 (2801)
2014 (1980)
2013 (1529)
2012 (1622)
2011 (1613)
2010 (1423)
Location
Africa (88)
Arizona (2)
Asia (2254)
Australia (293)
California (240)
Canada (56)
China (41)
Colorado (3)
Connecticut (5)
Delaware (8)
Europe (18560)
Florida (13)
Georgia (3)
Idaho (1)
Illinois (8)
India (3)
Indiana (3)
Japan (8)
Kansas (4)
Louisiana (1)
Maryland (14)
Massachusetts (174)
Michigan (4)
Minnesota (10)
Nebraska (1)
New Hampshire (3)
New Jersey (58)
New Mexico (1)
New York (155)
North Carolina (22)
Northern California (167)
Ohio (1)
Oregon (2)
Pennsylvania (39)
Rhode Island (1)
South America (106)
South Carolina (1)
Southern California (57)
Texas (55)
Utah (7)
Virginia (3)
Washington D.C. (2)
Washington State (7)
Wisconsin (1)
44,292 Results for "sanofi france".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
I&I
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can achieve deep B cell depletion, giving it the potential to reset the immune system.
March 20, 2025
·
2 min read
·
Tristan Manalac
Earnings
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
January 30, 2025
·
2 min read
·
Dan Samorodnitsky
Legal
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that determine pricing and rebates for the drug.
February 7, 2025
·
2 min read
·
Tristan Manalac
Policy
Sanofi, Pfizer, AstraZeneca Pledge Nearly $2.16B in Total Investments in France
The major biopharma players have promised to increase their investments in France to help boost their respective global manufacturing and R&D capabilities, with Sanofi committing more than $1 billion.
May 13, 2024
·
2 min read
·
Tristan Manalac
Vaccines
Sanofi Hit With $250M Impairment After Scrapping J&J-Partnered
E. coli
Vaccine
Without providing specific data, Sanofi on Thursday announced that the experimental vaccine did not significantly prevent invasive
E. coli
disease versus placebo.
February 13, 2025
·
2 min read
·
Tristan Manalac
Business
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France’s President, has been named Executive Vice President, Global Head of Corporate Affairs.
June 21, 2024
·
3 min read
Deals
Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Healthcare Unit
Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French government taking a stake as well to ensure the business remains in the county.
October 21, 2024
·
2 min read
·
Annalee Armstrong
Podcast
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
October 23, 2024
·
1 min read
·
Heather McKenzie
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the radioligand space with a $110 million licensing deal with Orano Med and Texas biotech RadioMedix.
October 17, 2024
·
2 min read
·
Tristan Manalac
Editorial
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two late-stage relapsing MS studies.
September 6, 2024
·
3 min read
·
Greg Slabodkin
1 of 4,430
Next
